Literature DB >> 19143907

Combination of doxazosin and sildenafil exerts an additive relaxing effect compared with each compound alone on human cavernosal and prostatic tissue.

Stéphanie Oger1, Delphine Behr-Roussel, Diane Gorny, Olivier Lecoz, Thierry Lebret, Yves Denoux, Antoine Faix, Albert Leriche, Chris Wayman, Laurent Alexandre, François Giuliano.   

Abstract

INTRODUCTION: Phosphodiesterase 5 inhibitors (PDE5) such as sildenafil are first-line treatment for erectile dysfunction (ED). Alpha1 (alpha1)-adrenoceptor antagonists such as doxazosin are indicated for the treatment of patients with lower urinary tract symptoms (LUTS)/benign prostatic hyperplasia (BPH). ED and LUTS/BPH are conditions that are often associated. Accordingly, alpha1-adrenoceptor antagonists and PDE5 inhibitors will be often prescribed in real life setting together. AIM: To evaluate the effects of the combination of sildenafil and doxazosin on human cavernosal and prostatic tissue.
METHODS: Prostatic and erectile tissues were obtained from nine to 12 patients, respectively. Patients underwent cystoprostatectomy for infiltrating bladder cancer or penile surgery for penile implant, congenital curvature or Peyronie's disease. MAIN OUTCOME MEASURES: In organ baths, prostatic and cavernosal strips were submitted to either concentration-response curves (CRC) to phenylephrine (Phe) or norepinephrine (NE), respectively, in presence of vehicle, sildenafil (10(-6) M, 10(-5) M), doxazosin (10(-8) M, 3.10(-8) M, or 10(-7) M), or a combination of both. Continuous electrical field stimulation (EFS; 32 Hz, 5 ms, 5 seconds, 300 mA) was performed on prostatic strips which were incubated with sildenafil 10(-6) M or vehicle before the successive addition of doxazosin (10(-7) M, 10(-6) M) or vehicle. Cavernosal strips were pre-incubated with doxazosin (10(-9) M, 10(-8) M) or vehicle, then CRC to sildenafil were constructed on NE (3.10(-6) M) precontracted cavernosal strips.
RESULTS: Combination of sildenafil and doxazosin exerted a greater relaxing effect on CRC to Phe or NE compared with each compound alone in both tissues. Sildenafil significantly enhanced the relaxing effect of doxazosin on EFS-induced contractions in prostatic strips. Doxazosin significantly increased the ability of sildenafil to inhibit NE-induced contractions in cavernosal strips.
CONCLUSIONS: Sildenafil and doxazosin reduced adrenergic tone of prostatic and cavernosal smooth muscle and their combination provided a significant benefit when targeting relaxation of both tissues. These experiments provide support for further clinical evaluation of the sildenafil and doxazosin combination in ED patients with LUTS/BPH.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19143907     DOI: 10.1111/j.1743-6109.2008.01138.x

Source DB:  PubMed          Journal:  J Sex Med        ISSN: 1743-6095            Impact factor:   3.802


  10 in total

Review 1.  An overview of prostate diseases and their characteristics specific to Asian men.

Authors:  Shu-Jie Xia; Di Cui; Qi Jiang
Journal:  Asian J Androl       Date:  2012-02-06       Impact factor: 3.285

Review 2.  Combination therapy for erectile dysfunction: an update review.

Authors:  Rohit R Dhir; Hao-Cheng Lin; Steven E Canfield; Run Wang
Journal:  Asian J Androl       Date:  2011-03-21       Impact factor: 3.285

3.  An open, comparative, multicentre clinical study of combined oral therapy with sildenafil and doxazosin GITS for treating Chinese patients with erectile dysfunction and lower urinary tract symptoms secondary to benign prostatic hyperplasia.

Authors:  Zhe Jin; Zhi-Chao Zhang; Ji-Hong Liu; Jun Lu; Yu-Xin Tang; Xiang-Zhou Sun; Wei-Dong Song; Bing Gao; Ying-Lu Guo; Zhong-Cheng Xin
Journal:  Asian J Androl       Date:  2011-05-23       Impact factor: 3.285

4.  Signalling pathways involved in sildenafil-induced relaxation of human bladder dome smooth muscle.

Authors:  S Oger; D Behr-Roussel; D Gorny; T Lebret; P Validire; X Cathelineau; L Alexandre; F Giuliano
Journal:  Br J Pharmacol       Date:  2010-07       Impact factor: 8.739

5.  Inhibition of human prostate smooth muscle contraction by the LIM kinase inhibitors, SR7826 and LIMKi3.

Authors:  Qingfeng Yu; Christian Gratzke; Yiming Wang; Annika Herlemann; Christian Maximilian Sterr; Beata Rutz; Anna Ciotkowska; Xiaolong Wang; Frank Strittmatter; Christian G Stief; Martin Hennenberg
Journal:  Br J Pharmacol       Date:  2018-04-29       Impact factor: 8.739

Review 6.  Novel drug targets for the pharmacotherapy of benign prostatic hyperplasia (BPH).

Authors:  S Ventura; V l Oliver; C W White; J H Xie; J M Haynes; B Exintaris
Journal:  Br J Pharmacol       Date:  2011-07       Impact factor: 8.739

7.  Pathogenic mechanisms linking benign prostatic hyperplasia, lower urinary tract symptoms and erectile dysfunction.

Authors:  Sidney Glina; Felipe Placco Araujo Glina
Journal:  Ther Adv Urol       Date:  2013-08

8.  Urodynamic effects of the combination of tamsulosin and daily tadalafil in men with lower urinary tract symptoms secondary to benign prostatic hyperplasia: a randomized, placebo-controlled clinical trial.

Authors:  Rommel Prata Regadas; Ricardo Reges; João Batista Gadelha Cerqueira; Daniel Gabrielle Sucupira; Iatagan Rocha Josino; Emmanuel Almeida Nogueira; Francisco Vagnaldo F Jamacaru; Manoel Odorico de Moraes; Lúcio Flávio Gonzaga Silva
Journal:  Int Urol Nephrol       Date:  2012-10-30       Impact factor: 2.370

9.  Efficacy of tamsulosin and tadalafil in relieving benign prostatic hyperplasia related symptoms: A randomized double blind placebo controlled cross-over study.

Authors:  Smita Pattanaik; Harbhupinder Singh Sandhu; Ravimohan Suryanarayan Mavuduru; Shrawan Kumar Singh; Arup Kumar Mandal
Journal:  Indian J Urol       Date:  2019 Jan-Mar

10.  Assessment of Combination Therapies vs Monotherapy for Erectile Dysfunction: A Systematic Review and Meta-analysis.

Authors:  Ioannis Mykoniatis; Nikolaos Pyrgidis; Ioannis Sokolakis; Andreas Ouranidis; Petros Sountoulides; Anna-Bettina Haidich; Koenraad van Renterghem; Georgios Hatzichristodoulou; Dimitrios Hatzichristou
Journal:  JAMA Netw Open       Date:  2021-02-01
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.